Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jennifer Guimbellot to Aminophenols

This is a "connection" page, showing publications Jennifer Guimbellot has written about Aminophenols.

 
Connection Strength
  
 
 
7.262
  
  1. Liu Z, Anderson JD, Rose NR, Baker EH, Dowell AE, Ryan KJ, Acosta EP, Guimbellot JS. Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia. Pulm Pharmacol Ther. 2024 Sep; 86:102314.
    View in: PubMed
    Score: 0.933
  2. Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024 Sep; 86:102301.
    View in: PubMed
    Score: 0.926
  3. Smith M, Ryan KJ, Gutierrez H, Sanchez LHG, Anderson JN, Acosta EP, Benner KW, Guimbellot JS. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. J Cyst Fibros. 2022 01; 21(1):e8-e10.
    View in: PubMed
    Score: 0.755
  4. Anderson JD, Liu Z, Odom LV, Kersh L, Guimbellot JS. CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling. Am J Physiol Lung Cell Mol Physiol. 2021 07 01; 321(1):L119-L129.
    View in: PubMed
    Score: 0.752
  5. Guimbellot JS, Baines A, Paynter A, Heltshe SL, VanDalfsen J, Jain M, Rowe SM, Sagel SD. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. J Cyst Fibros. 2021 03; 20(2):213-219.
    View in: PubMed
    Score: 0.727
  6. Guimbellot JS, Ryan KJ, Anderson JD, Liu Z, Kersh L, Esther CR, Rowe SM, Acosta EP. Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. J Cyst Fibros. 2020 09; 19(5):742-745.
    View in: PubMed
    Score: 0.688
  7. Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2019 01; 18(1):102-109.
    View in: PubMed
    Score: 0.607
  8. Guimbellot JS, Acosta EP, Rowe SM. Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 05; 53(5):E6-E8.
    View in: PubMed
    Score: 0.601
  9. Baker E, Harris WT, Guimbellot JS, Bliton K, Rowe SM, Raju SV, Oates GR. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL). J Cyst Fibros. 2024 Sep; 23(5):959-966.
    View in: PubMed
    Score: 0.234
  10. Young D, Bartlett LE, Guimbellot J, Milinic T, Burdis N, Gill ER, Lease ED, Goss CH, Kapnadak SG, Ramos KJ. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant. J Cyst Fibros. 2024 May; 23(3):545-548.
    View in: PubMed
    Score: 0.222
  11. Guimbellot JS, Ryan KJ, Anderson JD, Parker KL, Victoria Odom L, Rowe SM, Acosta EP. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis. Pediatr Pulmonol. 2022 11; 57(11):2745-2753.
    View in: PubMed
    Score: 0.205
  12. Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med. 2021 07; 9(7):677-679.
    View in: PubMed
    Score: 0.187
  13. Secunda KE, Guimbellot JS, Jovanovic B, Heltshe SL, Sagel SD, Rowe SM, Jain M. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males. Am J Respir Crit Care Med. 2020 04 15; 201(8):996-998.
    View in: PubMed
    Score: 0.174
  14. Guimbellot JS, Leach JM, Chaudhry IG, Quinney NL, Boyles SE, Chua M, Aban I, Jaspers I, Gentzsch M. Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight. 2017 11 16; 2(22).
    View in: PubMed
    Score: 0.147
  15. Ryan KJ, Guimbellot JS, Dowell AE, Reed-Walker KD, Kerstner-Wood CD, Anderson JD, Liu Z, Acosta EP. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Dec 15; 1213:123518.
    View in: PubMed
    Score: 0.052
  16. Ramos KJ, Guimbellot JS, Valapour M, Bartlett LE, Wai TH, Goss CH, Pilewski JM, Faro A, Diamond JM. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients. J Cyst Fibros. 2022 09; 21(5):745-752.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.